preval
asthma
chronic
obstruct
pulmonari
diseas
copd
continu
increas
exceed
million
million
worldwid
respect
asthma
copd
heterogen
clinic
characterist
cellular
sourc
inflamm
caus
exacerb
respons
therapi
share
similar
featur
symptom
airflow
limit
bronchial
hyperrespons
inflammatori
profil
previou
examin
asthma
copd
biolog
cluster
stabl
diseas
demonstr
overlap
sputum
inflammatori
profil
howev
understand
distinct
common
heterogen
diseas
exacerb
remain
elus
despit
current
guidelin
manag
strategi
asthma
copd
mani
patient
still
experi
exacerb
asthma
exacerb
impair
healthrel
qualiti
life
result
lost
product
increas
health
care
resourc
use
moreov
copd
exacerb
associ
acceler
loss
lung
function
poorer
healthrel
qualiti
life
comorbid
signific
mortal
increas
health
care
cost
standard
treatment
asthma
copd
exacerb
includ
use
bronchodil
corticosteroid
antibiot
littl
attent
paid
underli
heterogen
exacerb
biolog
heterogen
copd
exacerb
demonstr
previous
sputum
level
serum
level
peripher
blood
eosinophil
count
best
identifi
bacteria
viru
eosinophilassoci
exacerb
respect
howev
whether
biolog
heterogen
similar
asthma
copd
exacerb
unknown
main
object
studi
identifi
degre
overlap
biolog
cluster
asthma
copd
exacerb
deriv
sputum
mediat
profil
measur
airway
inflamm
determin
airway
bacteri
ecolog
cluster
patient
sever
asthma
moderatetosever
copd
recruit
singl
center
glenfield
hospit
leicest
unit
kingdom
assign
asthma
copd
group
made
patient
physician
consist
definit
asthma
copd
base
global
initi
asthma
global
initi
chronic
obstruct
lung
diseas
guidelin
respect
asthmat
patient
particip
publish
stabl
studi
patient
copd
particip
publish
exacerb
studi
patient
assess
stabl
state
least
week
exacerb
assess
exacerb
defin
increas
symptom
necessit
cours
oral
corticosteroid
antibiot
therapi
patient
provid
written
inform
consent
studi
approv
local
leicestershir
northamptonshir
rutland
ethic
committe
demograph
clinic
lung
function
data
includ
prebronchodil
postbronchodil
fev
forc
vital
capac
collect
patient
ask
score
sever
dyspnea
cough
use
visual
analog
scale
va
va
horizont
line
mm
length
anchor
word
descriptor
end
use
absenc
breathless
cough
one
end
maximum
breathless
cough
end
score
measur
distanc
left
end
mark
indic
patient
bacteri
associ
exacerb
defin
colonyform
unit
greater
ml
sputum
posit
cultur
result
microbiom
commun
obtain
rrna
sequenc
bacteri
genom
dna
extract
sputum
sampl
use
qiagen
dna
mini
kit
qiagen
valencia
calif
describ
previous
sequenc
read
process
use
qiim
pipelin
rna
extract
select
sputum
plug
rtpcr
panel
common
respiratori
virus
rhinovirus
picornavirus
respiratori
syncyti
viru
human
parainfluenza
virus
copd
chronic
obstruct
pulmonari
diseas
receptor
pf
ratio
proteobacteriafirmicut
ratio
type
type
tnfr
tnf
receptor
va
visual
analog
scale
vegf
vascular
endotheli
growth
factor
adenovirus
influenza
virus
b
coronaviru
human
metapneumoviru
human
bocaviru
undertaken
copd
sampl
describ
previous
asthma
sampl
method
use
viru
detect
limit
rhinovirus
picornavirus
respiratori
syncyti
viru
influenza
virus
b
virusassoci
exacerb
defin
exacerb
viru
detect
inflammatori
mediat
measur
sputum
supernat
serum
use
meso
scale
discoveri
platform
msd
gaithersburg
md
mediat
measur
select
reflect
cytokin
chemokin
proinflammatori
mediat
implic
airway
diseas
perform
msd
platform
recoveri
spike
exogen
recombin
protein
describ
previous
sputum
serum
inflammatori
mediat
level
less
detect
rang
replac
correspond
halv
lower
limit
quantif
addit
mediat
level
less
limit
quantif
patient
exclud
analysi
factor
cluster
analys
approach
perform
identifi
common
distinct
biolog
subgroup
asthma
copd
first
factor
analysi
appli
panel
sputum
inflammatori
mediat
reduc
small
independ
factor
sampl
adequaci
factor
analysi
assess
use
kaisermeyerolkin
test
optim
factor
retain
base
scree
plot
factor
break
curv
eigenvalu
greater
subsequ
correspond
factor
score
repres
patient
gener
use
input
variabl
kmean
cluster
algorithm
identifi
cluster
optim
number
cluster
chosen
base
scree
plot
cluster
break
curv
plot
within
cluster
sum
squar
seri
sequenti
number
cluster
addit
linear
discrimin
analysi
perform
sputum
mediat
across
cluster
valid
identifi
cluster
factor
score
predict
use
actual
mediat
measur
identifi
contribut
mediat
discrimin
cluster
data
shown
discrimin
score
individu
patient
calcul
use
repres
patient
biolog
cluster
membership
graphic
microbiom
measur
rrna
sequenc
phylum
genu
level
perform
thirti
speci
phylum
level
speci
genu
level
screen
rel
abund
speci
calcul
alpha
withinpati
beta
betweenpati
divers
phylum
genu
level
estim
use
shannonwein
sorensen
indic
respect
vegan
rpackag
version
pattern
compar
diseas
identifi
biolog
cluster
addit
pattern
abund
speci
median
rel
abund
greater
andor
known
major
airway
pathogen
asthmat
patient
patient
copd
phylum
genu
level
present
graphic
across
diseas
identifi
biolog
cluster
statist
summari
avail
characterist
present
across
diseas
identifi
biolog
cluster
within
cluster
diseas
subgroup
cluster
interpret
accord
pattern
characterist
addit
chang
clinic
characterist
mediat
stabl
exacerb
state
within
cluster
assess
parametr
data
present
mean
sem
logtransform
data
present
geometr
mean
ci
x
fisher
exact
test
anova
use
compar
percentag
mean
across
group
nonparametr
data
present
median
valu
first
third
quartil
kruskalw
test
use
compar
data
cluster
statist
analys
perform
spss
softwar
version
ibm
armonk
ny
stataic
version
softwar
window
statacorp
colleg
station
tex
r
softwar
version
r
foundat
statist
comput
vienna
austria
thirtytwo
asthmat
patient
patient
copd
sputum
mediat
record
exacerb
includ
studi
demograph
clinic
characterist
sputum
mediat
summar
across
diseas
tabl
articl
onlin
repositori
wwwjacionlin
org
inhal
corticosteroid
dose
differ
asthmat
patient
patient
copd
asthmat
patient
receiv
longact
bagonist
treatment
patient
copd
receiv
longact
bagonist
andor
longact
muscarin
antagonist
asthmat
patient
younger
obes
better
lung
function
patient
copd
va
score
cellular
profil
bacteriaassoci
exacerb
significantli
differ
diseas
level
sever
sputum
mediat
receptor
significantli
increas
asthmat
patient
versu
patient
copd
wherea
level
tnf
receptor
tnfr
significantli
increas
patient
copd
versu
asthmat
patient
howev
level
major
mediat
tnfa
vascular
endotheli
growth
factor
vegf
ifng
significantli
differ
asthmat
patient
patient
copd
see
tabl
similarli
level
serum
mediat
tnfa
increas
asthmat
patient
versu
level
increas
patient
copd
other
vegf
differ
group
see
tabl
fourteen
asthmat
patient
patient
copd
sputum
mediat
exacerb
also
provid
suffici
sputum
microbiom
analysi
alpha
divers
phylum
genu
level
differ
asthma
copd
group
shown
fig
articl
onlin
repositori
wwwjacionlineorg
beta
divers
asthmat
patient
patient
copd
phylum
level
genu
level
beta
divers
asthmat
patient
patient
copd
phyla
genera
median
rel
abund
greater
actinobacteria
bacteroidet
firmicut
proteobacteria
phylum
level
actinomyc
rothia
speci
phylum
actinobacteria
lactobacillu
streptococcu
speci
phylum
firmicut
neisseria
haemophilu
moraxella
pseudomona
speci
phylum
proteobacteria
genu
level
rel
abund
abund
phyla
andor
known
major
airway
pathogen
across
asthmat
patient
patient
copd
proteobacteriafirmicut
ratio
pf
ratio
asthmat
patient
versu
patient
copd
present
see
fig
phylum
level
airway
ecolog
similar
asthmat
patient
patient
copd
bacteroidet
significantli
increas
asthmat
patient
compar
patient
copd
see
fig
rel
abund
abund
clinic
relev
genera
streptococcu
haemophilu
moraxella
also
significantli
differ
asthmat
patient
patient
copd
see
fig
factor
analysi
varimax
rotat
perform
use
sputum
mediat
exacerb
asthmat
patient
patient
copd
factor
retain
level
less
limit
detect
patient
level
miss
sever
patient
therefor
valu
exclud
factor
cluster
analys
howev
pattern
assess
identifi
biolog
subgroup
rotat
factor
load
depict
tabl
articl
onlin
repositori
wwwjacionlineorg
indic
relationship
factor
mediat
proinflammatori
mediat
appear
load
togeth
factor
type
mediat
factor
type
mediat
factor
three
biolog
cluster
identifi
use
factor
score
deriv
sputum
mediat
input
kmean
cluster
algorithm
pattern
clinic
paramet
sputum
mediat
present
across
identifi
cluster
tabl
ii
respect
serum
mediat
across
cluster
shown
tabl
articl
onlin
repositori
wwwjacionlineorg
summari
data
clinic
paramet
sputum
serum
mediat
asthmat
patient
patient
copd
within
cluster
present
tabl
articl
onlin
repositori
wwwjacionlineorg
respect
signific
differ
age
sex
smoke
statu
packyear
histori
bodi
mass
index
frequenc
exacerb
corticosteroid
dosag
symptom
score
lung
function
cluster
cluster
present
graphic
across
first
discrimin
score
fig
microbiom
data
avail
patient
asthmat
patient
patient
copd
cluster
patient
asthmat
patient
patient
copd
cluster
patient
asthmat
patient
patient
copd
cluster
alpha
divers
proport
pattern
rel
abund
abund
phyla
pf
ratio
present
cluster
fig
similarli
alpha
divers
proport
pattern
rel
abund
abund
genera
present
fig
chang
characterist
stabl
exacerb
state
within
cluster
report
clinic
paramet
sputum
mediat
tabl
iii
serum
mediat
tabl
articl
onlin
repositori
wwwjacionlineorg
breakdown
characterist
diseas
within
cluster
report
tabl
articl
onlin
repositori
wwwjacionlineorg
respect
exacerb
prebronchodil
postbronchodil
fev
decreas
wherea
va
score
cough
dyspnea
increas
significantli
cluster
signific
differ
cluster
cluster
cluster
copdpredomin
group
patient
asthmat
patient
patient
copd
men
group
mean
age
year
current
smoker
exsmok
patient
cluster
increas
blood
sputum
neutrophil
count
sputum
proinflammatori
mediat
level
tnfa
vegf
greater
proport
bacteriaassoci
exacerb
compar
cluster
addit
group
greater
proteobacteria
pf
ratio
fig
beta
divers
phylum
genu
level
respect
compar
stabl
state
blood
sputum
neutrophil
count
sputum
total
cell
count
concentr
tnfa
vegf
ifng
increas
significantli
sputum
eosinophil
macrophag
count
level
significantli
lower
tabl
iii
serum
level
increas
level
decreas
exacerb
compar
stabl
visit
see
tabl
cluster
cluster
consist
patient
asthmat
patient
patient
copd
men
mean
age
year
current
smoker
exsmok
patient
cluster
increas
sputum
blood
eosinophil
count
increas
level
sputum
serum
mediat
tabl
see
tabl
cluster
exhibit
significantli
greater
alpha
divers
microbiom
greater
proport
bacteroidet
phylum
level
compar
cluster
fig
beta
divers
phylum
genu
level
respect
pair
comparison
stabl
exacerb
state
sputum
level
significantli
increas
exacerb
wherea
contrast
serum
tnfa
level
decreas
tabl
iii
see
tabl
cluster
cluster
consist
patient
asthmat
patient
patient
copd
men
mean
age
year
current
smoker
exsmok
patient
cluster
increas
level
mediat
ifng
sputum
tabl
serum
level
see
tabl
greater
proport
actinobacteria
firmicut
phylum
level
streptococcu
phylum
firmicut
genu
level
lesser
proport
proteobacteria
pf
ratio
fig
beta
divers
phylum
genu
level
blood
eosinophil
count
sputum
concentr
lower
tnfa
ifng
concentr
greater
exacerb
compar
stabl
state
tabl
iii
serum
level
increas
exacerb
versu
stabl
state
serum
level
decreas
see
tabl
chang
within
cluster
highest
load
factor
sputum
stabl
exacerb
state
shown
fig
articl
onlin
repositori
wwwjacionlineorg
sputum
level
increas
significantli
cluster
respect
concentr
mediat
also
increas
stabl
state
sputum
concentr
increas
exacerb
cluster
contrast
level
mediat
differ
group
stabl
state
chang
stabl
state
exacerb
asthmat
patient
patient
copd
within
cluster
shown
tabl
studi
exacerb
biolog
cluster
identifi
use
combin
factor
cluster
analys
cluster
differ
percentag
asthmat
patient
patient
copd
interestingli
cluster
seem
demonstr
distinct
biolog
plausibl
inflammatori
profil
cluster
copdpredomin
group
evid
neutrophil
inflamm
increas
proinflammatori
mediat
bacteriaassoci
exacerb
proport
proteobacteria
pf
ratio
phylum
level
patient
cluster
exhibit
evid
eosinophil
inflamm
increas
level
mediat
proport
bacteroidet
patient
cluster
greater
mediat
level
greater
proport
actinobacteria
firmicut
phylum
level
importantli
comparison
assess
perform
patient
stabl
demonstr
level
proinflammatori
mediat
increas
exacerb
cluster
respect
wherea
eosinophil
inflamm
mediat
level
decreas
cluster
exacerb
cluster
proinflammatori
mediat
level
also
increas
stabl
state
respect
therefor
find
indic
exacerb
biolog
cluster
share
asthma
copd
addit
inflammatori
profil
cluster
increas
compar
stabl
state
associ
distinct
airway
bacteri
ecolog
strength
studi
abil
use
statist
techniqu
appli
previous
asthma
copd
independ
character
biolog
heterogen
asthma
copd
combin
use
sputum
mediat
assess
protocol
analyt
platform
similar
differ
asthma
copd
identifi
compar
characterist
diseas
level
publish
simpl
separ
approach
might
reflect
underli
biolog
heterogen
provid
insight
multidimension
characterist
diseas
cluster
analysi
uncov
biolog
cluster
within
diseas
uncov
common
distinct
meaning
subgroup
diseas
evid
diseas
level
extend
examin
deriv
biolog
cluster
includ
associ
airway
bacteri
ecolog
aid
understand
pathophysiolog
connect
outcom
airway
diseas
toward
realiz
potenti
new
biomark
target
therapi
instanc
cluster
neutrophil
inflamm
increas
proinflammatori
mediat
level
bacteriaassoci
exacerb
repres
group
would
like
respond
antibiot
role
antibiot
prevent
copd
exacerb
antibiot
patient
admit
intens
care
unit
copd
exacerb
also
appear
benefici
still
continu
uncertainti
asthmat
patient
macrolid
antibiot
provid
benefit
patient
stabl
diseas
wherea
patient
acut
exacerb
benefit
demonstr
telithromycin
azithromycin
latter
studi
almost
half
screen
alreadi
receiv
antibiot
primari
care
studi
underpow
lack
respons
observ
might
consequ
failur
includ
like
respond
antibiot
advanc
cultureindepend
techniqu
studi
role
lung
microbiom
respiratori
diseas
better
extent
interest
wang
et
al
found
lung
microbiom
dynam
associ
copd
exacerb
therefor
identif
biomark
biolog
cluster
evid
microbi
dysbiosi
might
enabl
futur
target
antibiot
trial
pf
ratio
also
emerg
possibl
simpl
measur
reflect
bacteri
composit
whether
appli
futur
intervent
studi
guid
therapi
need
test
cluster
would
seem
like
respond
therapi
target
eosinophil
inflamm
target
eosinophil
inflamm
asthmat
patient
patient
copd
corticosteroid
reduc
exacerb
frequenc
likewis
mab
therapi
target
cytokin
receptor
effect
decreas
risk
exacerb
patient
eosinophil
asthma
evid
benefit
although
less
consist
patient
eosinophil
copd
find
pivot
phase
iii
studi
evalu
efficaci
safeti
mepolizumab
mab
addit
standard
care
patient
copd
demonstr
reduct
frequenc
moderatetosever
exacerb
higher
blood
eosinophil
count
studi
underscor
import
eosinophil
phenotyp
asthmat
patient
patient
copd
futur
studi
need
consid
whether
underli
mechan
common
asthmat
patient
patient
copd
one
limit
ige
level
assess
exacerb
role
allergi
could
explor
futur
studi
interferoninduc
chemokin
sputum
serum
increas
cluster
also
increas
significantli
exacerb
compar
stabl
state
biolog
cluster
high
level
interferoninduc
chemokin
observ
previous
patient
stabl
asthma
copd
chemokin
identifi
biomark
virusassoci
exacerb
would
seem
like
viral
infect
possibl
trigger
cluster
would
amen
futur
antivir
intervent
consist
proport
virusassoci
exacerb
greater
cluster
reach
statist
signific
cluster
asthma
copd
combin
independ
viral
identif
challeng
especi
sputum
viral
load
peak
peak
lower
respiratori
symptom
therefor
find
like
underrepres
proport
virusassoci
exacerb
one
major
limit
studi
number
patient
asthma
small
percentag
asthmat
patient
patient
copd
provid
suffici
sampl
studi
microbi
ecolog
approxim
half
patient
remain
patient
unabl
produc
suffici
sputum
analysi
clinic
characterist
versu
provid
sampl
microbiolog
assess
similar
suggest
group
compar
exclud
possibl
acquisit
bia
toward
microbi
ecolog
associ
sputum
product
notwithstand
limit
find
consist
differ
microbi
ecolog
cluster
second
demonstr
stabil
exacerb
biolog
cluster
base
assess
singl
exacerb
therefor
find
need
explor
larger
multicent
studi
anoth
limit
size
studi
could
analyz
patient
accord
sever
asthma
copd
sever
exacerb
control
baselin
therapi
asthmat
patient
patient
copd
howev
corticosteroid
dosag
similar
group
indic
unlik
differenti
effect
underli
inflammatori
microbi
profil
limit
cluster
analysi
specif
data
set
studi
therefor
neither
asthma
copd
group
stabl
visit
analyz
independ
gener
proport
cluster
mean
cluster
stabil
simpli
determin
howev
found
pattern
inflammatori
profil
similar
asthmat
patient
patient
copd
cluster
pattern
similar
stabl
exacerb
state
proinflammatori
cluster
eosinophil
cluster
phenotyp
amplif
underli
inflammatori
profil
exacerb
event
howev
mediat
increas
exacerb
cluster
increas
stabl
state
whether
stabl
state
mediat
profil
identifi
subject
like
respond
specif
antiinflammatori
antibiot
therapi
reduc
futur
exacerb
risk
requir
studi
includ
larg
number
cytokin
chemokin
analysi
still
reflect
minor
number
mediat
present
sputum
serum
sampl
limit
avail
sampl
could
extend
studi
includ
import
mediat
eicosanoid
binterferon
metabolom
approach
somolog
might
provid
insight
inflammatori
mediat
network
consid
futur
studi
conclus
use
biolog
cluster
approach
look
asthma
copd
exacerb
identifi
copdpredomin
cluster
evid
neutrophil
inflamm
increas
proinflammatori
mediat
level
bacteriaassoci
exacerb
cluster
evid
eosinophil
inflamm
increas
mediat
level
cluster
increas
mediat
level
studi
aid
understand
heterogen
asthma
copd
exacerb
suggest
endotyp
might
import
asthma
copd
diagnosi
highlight
need
research
develop
novel
biomark
predict
diseas
outcom
guid
target
therapi
clinic
implic
sputum
mediat
microbiom
profil
determin
distinct
overlap
asthma
copd
biolog
exacerb
cluster
highlight
heterogen
exacerb
data
present
geometr
mean
ci
signific
differ
asthmat
patient
patient
copd
within
cluster
signific
differ
anova
cluster
asthmat
patient
patient
copd
